- Jul 23, 2020
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
- Jul 23, 2020
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
- Jul 23, 2020
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
- Jul 22, 2020
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
- Jul 22, 2020
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
- Jul 22, 2020
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
- Jul 17, 2020
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
- Jul 17, 2020
NCT04407442: Phase 2: Dara, Azacitidine & Dex for RRMM Myeloma Previously Treated With Daratumumab
- Jul 17, 2020
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
- Jul 16, 2020
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
- Jul 16, 2020
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
- Jul 15, 2020
Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients
- Jul 15, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
- Jul 15, 2020
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
- Jul 14, 2020
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
- Jul 10, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
- Jul 10, 2020
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
- Jul 10, 2020
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
- Jul 10, 2020
Allogenic CAR T Explained by Precision BioSciences